Description
Build high-quality cardiotoxicity models in 7 days.
Ensure confidence in your workflow with high-quality axoCellsTM ventricular cardiomyocytes differentiated from human induced pluripotent stem cells (iPSCs). Derived from consenting donor fibroblasts, our ventricular cardiomyocytes have been specifically developed for use in drug validation and cardiotoxicity screening.
With Axol, you can rely on physiologically relevant cardiomyocytes that can detect action potential duration prolongation and triangulation associated with hERG block and torsades de pointes (TdP), and have been validated against all 28 CiPA compounds, correctly identifying cardiotoxic liability. Further MEA studies have confirmed the correct response to all the major classes of cardioactive drugs. With our functionally relevant and mature cardiomyocytes, you can build robust in vitro models for drug validation and cardiotoxicity screening.
Supporting quality and consistency
Confidently carry out your workflow with iPSCs manufactured in our ISO:9001-accredited production facility, guided by our rigorous quality control procedures and decades of scientific experience. All cells come with a full Certificate of Analysis and are officially certified by HPSCreg®, to ensure ethical and biological conformity for your peace of mind.
Join our customer base of top ten biopharma and academic institutions in building robust, physiologically relevant disease models for research and drug discovery.
How to get highly functional axoCells Ventricular Cardiomyocytes
To ensure simplicity and effectiveness, we’ve developed a kit containing iPSC-derived cells that have been directed down a ventricular cardiomyocyte end-type lineage. Using the easy-to-follow protocol, you can rapidly mature these cells into functional ventricular cardiomyocytes in just 7 days.
- You’ll need a ventricular cardiomyocyte kit ax2500.
- Follow the protocol for use on cell culture plates.
- 7 days later you will have highly functional ventricular cardiomyocytes
*Additional third party components are required. Be sure to check the protocol before you start using the ventricular cardiomyocyte kit.
Need a quote for this single product or for the whole cell + media + reagent kit? We’re here to help! Click the ‘get a quote’ button or send an email to operations@axolbio.com
Product Highlights
- Accelerate workflow with cells that spontaneously beat 3 days post-thaw and are assay ready in just 7 days
- Validated against all 28 CiPA compounds
- Ensure confidence with high-quality cells manufactured in our ISO:9001-accredited production facility under rigorous quality control procedures
- Designed for use in drug validation and cardiotoxicity screening
- Used by leading Biopharma and academic institutions around the world for robust drug validation and cardiotoxicity testing
Applications
axoCells ventricular cardiomyocytes can be used to measure a variety of cardiac responses on a number of platforms: action potentials and waveform analysis (patch clamp, automated patch clamp, voltage sensitive dyes (VSD), microelectrode arrays (MEA)), contractility/impedence (FLEXcyte, xCELLigence RTCA), calcium responses (Hamamatsu FDSS µCell, Cell Optiq), morphology (immunocytochemistry) and transcriptomics (RNAseq, qPCR). They have also been used to investigate disease states such as septic cardiomyopathy.
Protocols
Protocols for the culture of ventricular cardiomyocytes on tissue culture plates, xCELLigence RTCA, FLEXCyte system, Cell Optiq, Hamatatsu FDSS µCell and Axion Maestro Pro are available.
Quality
We maintain or exceed industry-level quality with our ISO:9001-accredited production facility, guided by our rigorous quality control procedures and decades of scientific experience.
All cells come with a full Certificate of Analysis and are officially certified by HPSCreg®, to ensure ethical and biological conformity for your peace of mind.
Licenses & Consent
Axol has obtained all relevant licenses for reprogramming donor samples into iPSCs and differentiating these into ventricular cardiomyocytes for commercial use.
Patient samples used to create these cells have been ethically sourced and consented for research and commercial use. All cells come with a full Certificate of Analysis and are officially certified by HPSCreg®, to ensure ethical and biological conformity for your peace of mind.
Publications
Sutton et al, 2017 Human Stem Cell-Derived Cardiomyocytes: In Vitro Assays and Screening Platforms for Exploring Ventricular and Atrial Phenotypes, J. Pharm. Tox Methods 88 2 2017 https://doi.org/10.1016/j.vascn.2017.09.243.
Kanade, P. P., Oyunbaatar, N. E., & Lee, D. W. (2021). Effects of low temperature on electrophysiology and mechanophysiology of human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs). Micro and Nano Systems Letters, 9(1), 1-7.
Zhang, Y., Le Friec, A., Sun, D., & Chen, M. (2023). Sinusoidal stretchable fibrous electrodes regulate cardiac contraction. Chemical Engineering Journal, 455, 140555.
Sucharit Ray et al., Membrane repair triggered by cholesterol-dependent cytolysins is activated by mixed lineage kinases and MEK. Sci. Adv. 8, eabl6367 (2022).DOI:10.1126/sciadv.abl6367
Media & Reagents
Optimized media (Cardiomyocyte Maintenance media ax2530-500) and plate coating (Fibronectin ax0049) for the culture of ventricular cardiomyocytes are available.
